Health Catalyst (HCAT) 주식 개요
는 미국 내 의료 기관에 데이터 및 분석 기술과 서비스를 제공합니다. 자세히 보기
HCAT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Health Catalyst, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$2.39 |
| 52주 최고가 | US$3.88 |
| 52주 최저가 | US$0.96 |
| 베타 | 1.56 |
| 1개월 변동 | 4.37% |
| 3개월 변동 | 50.31% |
| 1년 변동 | -37.43% |
| 3년 변동 | -80.82% |
| 5년 변동 | -95.45% |
| IPO 이후 변동 | -93.90% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Aug 05
HCAT: Cleaner Execution And Sector Rebound Will Shape 2026 Reset
Health Catalyst's analyst price targets have shifted higher into a $2 to $3 range, reflecting revised fair value estimates and updated models as analysts weigh sector rebounds, expectations for cleaner quarters, and company specific factors like the pending Vitalware sale. Analyst Commentary Bullish analysts covering Health Catalyst are pointing to a tighter, higher price target range as they refresh models ahead of upcoming earnings reports.
내러티브 업데이트 • Jul 21
HCAT: Cost Cuts And Cleaner Quarters Will Guide A Cautious Reset
Health Catalyst's analyst price targets have moved higher, with recent updates pointing to a range of around $1.75 to $3 as analysts factor in a lower discount rate, slightly less revenue decline, and expectations for cleaner quarters ahead. Analyst Commentary Recent Street research on Health Catalyst highlights a mix of optimism around the updated models and caution around execution risks into upcoming quarters.
내러티브 업데이트 • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.Recent updates
내러티브 업데이트 • Aug 05
HCAT: Cleaner Execution And Sector Rebound Will Shape 2026 Reset
Health Catalyst's analyst price targets have shifted higher into a $2 to $3 range, reflecting revised fair value estimates and updated models as analysts weigh sector rebounds, expectations for cleaner quarters, and company specific factors like the pending Vitalware sale. Analyst Commentary Bullish analysts covering Health Catalyst are pointing to a tighter, higher price target range as they refresh models ahead of upcoming earnings reports.내러티브 업데이트 • Jul 21
HCAT: Cost Cuts And Cleaner Quarters Will Guide A Cautious Reset
Health Catalyst's analyst price targets have moved higher, with recent updates pointing to a range of around $1.75 to $3 as analysts factor in a lower discount rate, slightly less revenue decline, and expectations for cleaner quarters ahead. Analyst Commentary Recent Street research on Health Catalyst highlights a mix of optimism around the updated models and caution around execution risks into upcoming quarters.내러티브 업데이트 • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.내러티브 업데이트 • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.내러티브 업데이트 • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.내러티브 업데이트 • May 09
HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.내러티브 업데이트 • Apr 24
HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further
Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.내러티브 업데이트 • Apr 08
HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.내러티브 업데이트 • Mar 25
HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound
Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.내러티브 업데이트 • Mar 11
HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.내러티브 업데이트 • Feb 24
HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential
Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.분석 기사 • Feb 13
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...내러티브 업데이트 • Feb 10
HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.내러티브 업데이트 • Jan 27
HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential
Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.내러티브 업데이트 • Jan 10
HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.내러티브 업데이트 • Dec 26
HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.내러티브 업데이트 • Dec 11
HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential
Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.내러티브 업데이트 • Nov 27
HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook
Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.내러티브 업데이트 • Nov 13
HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance
Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.분석 기사 • Oct 28
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...내러티브 업데이트 • Aug 30
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.분석 기사 • Aug 13
Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price
NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...내러티브 업데이트 • Aug 10
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.분석 기사 • Aug 04
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jun 10
Health Catalyst: Ignite Platform Is A Growth Catalyst
Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking Alpha분석 기사 • May 09
Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
새로운 내러티브 • Mar 30
Ignite Transition And Recent Acquisitions Will Expand Global Footprint
Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.Seeking Alpha • Mar 25
Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook
Summary Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. Risks include potential revenue stall, macroeconomic challenges, and stock price volatility, but I remain cautiously optimistic, looking for a breakout to add to my position. Read the full article on Seeking Alpha분석 기사 • Mar 08
Take Care Before Jumping Onto Health Catalyst, Inc. (NASDAQ:HCAT) Even Though It's 27% Cheaper
To the annoyance of some shareholders, Health Catalyst, Inc. ( NASDAQ:HCAT ) shares are down a considerable 27% in the...주주 수익률
| HCAT | US Healthcare Services | US 시장 | |
|---|---|---|---|
| 7D | 10.6% | 1.2% | 5.5% |
| 1Y | -37.4% | -30.6% | 20.8% |
수익률 대 산업: HCAT은 지난 1년 동안 -31.1%의 수익을 기록한 US Healthcare Services 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: HCAT은 지난 1년 동안 21.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| HCAT volatility | |
|---|---|
| HCAT Average Weekly Movement | 16.3% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: HCAT의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: HCAT의 주간 변동성(16%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 1,200 | Ben Albert | www.healthcatalyst.com |
는 미국의 의료 기관에 데이터 및 분석 기술과 서비스를 제공하는 회사입니다. 이 회사는 두 가지 부문으로 운영됩니다: 기술 및 전문 서비스. 이 회사는 고객에게 이질적인 소프트웨어 시스템의 데이터를 통합하고 구성할 수 있는 단일 종합 환경을 제공하는 이그나이트 데이터 및 분석 플랫폼과 임상 개선, 수익 및 비용 개선, 외래 운영, 측정 및 레지스트리, 데이터 및 분석 전반에 걸쳐 고객이 직면한 문제를 분석하기 위한 이그나이트 플랫폼용 소프트웨어 분석 애플리케이션인 애플리케이션을 제공합니다.
Health Catalyst, Inc. 기초 지표 요약
| HCAT 기초 통계 | |
|---|---|
| 시가총액 | US$168.48m |
| 순이익 (TTM) | -US$265.26m |
| 매출 (TTM) | US$302.48m |
0.6x
주가매출비율(P/S)-0.7x
주가수익비율(P/E)HCAT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| HCAT 손익계산서 (TTM) | |
|---|---|
| 매출 | US$302.48m |
| 매출원가 | US$149.90m |
| 총이익 | US$152.58m |
| 기타 비용 | US$417.83m |
| 순이익 | -US$265.26m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 06, 2026
| 주당순이익(EPS) | -3.59 |
| 총이익률 | 50.44% |
| 순이익률 | -87.69% |
| 부채/자본 비율 | 111.0% |
HCAT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/05 22:27 |
| 종가 | 2026/08/05 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Health Catalyst, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Zhilin Long | Berenberg |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |